Patients with cancer and VTE are at risk for VTE recurrence, and there are limited data on appropriate and effective anticoagulation regimens beyond 6 months...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and dec...